» Articles » PMID: 25756685

Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy

Overview
Journal Invest Radiol
Specialty Radiology
Date 2015 Mar 11
PMID 25756685
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The dentate nucleus of the cerebellum may appear as hyperintense on unenhanced T1 magnetic resonance images (MRIs) of the brain. Recently, T1 signal hyperintensity has received attention owing to data on the association of this finding with the history of multiple injections of gadolinium-based contrast agents, specifically gadodiamide, in patients with multiple sclerosis and brain metastases. We conducted a retrospective study on patients with a meningioma who had routinely undergone follow-up enhanced MRI scans with gadodiamide. Across a time interval of 18 months (from January 2013 to July 2014), we identified 102 consecutive patients eligible for this study. A significant increase in T1 hyperintensity of the dentate nuclei of the cerebellum on nonenhanced scans was observed between the first and the last MRI in the group of patients with a history of at least 6 enhanced MRI scans (P < 0.01), whereas no differences were observed in the group with 1 to 5 enhanced MRI scans (P = 0.74). Further research is necessary to shed light on the mechanism of the T1 hyperintensity as well as on the histological and microstructural appearance of the dentate nucleus after multiple intravenous injections of gadodiamide. The finding raises the question of substantial dechelation of this agent in patients with normal renal function.

Citing Articles

Comprehensive Analysis of the Spatial Distribution of Gadolinium, Iron, Manganese, and Phosphorus in the Brain of Healthy Rats After High-Dose Administrations of Gadodiamide and Gadobutrol.

Hummel L, Frenzel T, Boyken J, Pietsch H, Seeliger E Invest Radiol. 2023; 59(2):150-164.

PMID: 38157437 PMC: 11441738. DOI: 10.1097/RLI.0000000000001054.


MR Imaging Signs of Gadolinium Retention Are Not Associated with Long-Term Motor and Cognitive Outcomes in Multiple Sclerosis.

Scaravilli A, Tranfa M, Pontillo G, Falco F, Criscuolo C, Moccia M AJNR Am J Neuroradiol. 2023; 44(4):396-402.

PMID: 36863844 PMC: 10084901. DOI: 10.3174/ajnr.A7807.


The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients.

Asadollahzade E, Ghadiri F, Ebadi Z, Naser Moghadasi A Rev Assoc Med Bras (1992). 2022; 68(8):979-981.

PMID: 36134822 PMC: 9574993. DOI: 10.1590/1806-9282.20220643.


Do We Need Gadolinium-Based Contrast Agents for Routine MRI Surveillance of Unoperated Pituitary Macroadenoma?.

Alali A, Hanagandi P, Maralani P AJNR Am J Neuroradiol. 2022; 43(7):1024-1028.

PMID: 35738673 PMC: 9262062. DOI: 10.3174/ajnr.A7554.


How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo.

Do Q, Lenkinski R, Tircso G, Kovacs Z Molecules. 2022; 27(1).

PMID: 35011290 PMC: 8746842. DOI: 10.3390/molecules27010058.